Abstract:The designed and synthesized multifunctional properties of bis-hydrazono[1,3,4]thiadiazoles became important for developing an efficient medication for Alzheimer's disease. Thiadiazoles were characterized and studied towards this target as an acetylcholinesterase inhibitor (ChEIs). In this study, one-pot synthetic strategy was applied for the synthesis of bis-hydrazono[1,3,4]thiadiazole series from 2,2′-(1,2-diphenylethane-1,2-diylidene)bis(hydrazine-1-carbodithioic acid) and hydrazonoyl chlorides. The greener pastures, in silico, an environmentally-friendly and free computer-aided method, bioactivity studies of the bis-hydrazono[1,3,4]thiadiazoles 4a-h exhibited various possible interesting inhibitory activities against AChE showing similar behaviour to the approved drugs, Donepezil, Galantamine and Rivastigmine. For a fair comparison, the superpositions of 4a-h, and Donepezil, Galantamine and Rivastigmine docked together into the functional domain (binding pocket) of 1EVE to reveal interesting different molecular laydowns of the compounds. On the other side, the display of the molecules before and after docking was discussed. The binding affinity slightly differs between Donepezil, Galantamine, Rivastigmine, and the ligands 4a-h. The range of the recorded binding affinity for 4a-h is from (−9.4 to −8.4 kcal/mol −1 ) , whereas the binding affinity for Donepezil, Galantamine and Rivastigmine is (−11.1, −9.8 and −8.0 kcal/mol −1 respectively), which is higher than all the prepared ligands. Furthermore, the binding amino acids also varied among the studied compounds in this study. Phe290, Phe330, Phe331, Trp279, Tyr70, Tyr121 and Tyr334 are the common amino acids binding with the FDA-approved AChE inhibitors for treating AD, Donepezil, Galantamine and Rivastigmine and ligands. Notably, the number of hydrophobic and hydrogen interactions studied between the ligands 4a-h and the Donepezil, Galantamine and Rivastigmine drugs were compared as a preliminary indicator towards a successful inhibitor. The comparative study in this research work aims to rank our compounds with respect to the approved medications. This is a friendly environmental preliminary helpful indication before leaping into time and energy-consuming experimental work. Organ toxicological endpoints and toxicity-predicted activity were obtained using the ProTox-II web server for both the approved medication and ligands. Later, in-vitro acetylcholinesterase inhibition assays were conducted to assess the efficacy of bis-hydrazono[1,3,4]thiadiazoles 4a-h as inhibitors of acetylcholinesterase (AChE) in comparison to Donepezil. Results indicated promising inhibition activities for example 4 h, 4 g and 4d to the testing drug Donepezil for breaking down the neurotransmitter acetylcholine. Graphical abstract Download : Download high-res image (210KB) Download : Download full-size image

Novel Thiadiazole Derivatives as Potential Anti‐Alzheimer Agent: Synthesis, Activity of Molecular Interactions and their in Silico Assessment

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Novel bis-thiazole-thiazolidinone hybrid derivatives: Synthesis, structural properties and anticholinesterase bioactive potential as drug competitor based on docking studies

Design, synthesis and evaluation of N-arylmethylamide derivatives as cholinesterase inhibitors

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

Novel asymmetric biscarbothioamides as Alzheimer's disease associated cholinesterase inhibitors: synthesis, biological activity, and molecular docking studies

New 1,2,4-oxadiazole derivatives as potential multifunctional agents for the treatment of Alzheimer's disease: design, synthesis, and biological evaluation

Synthesis, Spectral Analysis and Molecular Docking Investigation of Thiadiazole Based Sulfonamide Derivatives: An Effective Approach Toward Alzheimer's Disease

Novel chalcone derivatives of ursolic acid as acetylcholinesterase inhibitors: Synthesis, characterization, biological activity, ADME prediction, molecular docking and molecular dynamics studies

Synthesis, in Vitro Cholinesterase Inhibition, Molecular Docking, DFT, and ADME Studies of Novel 1,3,4‐oxadiazole‐2‐thiol Derivatives

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

Development of promising acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, in vitro and in silico approaches of pyridine derived fused bis-oxadiazole and bis-thiadiazole derivatives

New thiourea and benzamide derivatives of 2-aminothiazole as multi-target agents against Alzheimer's disease: Design, synthesis, and biological evaluation

Design, synthesis, and biological evaluation of novel tryptanthrin derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

Synthesis and Biological Evaluation of 2-Arylbenzofuran Derivatives As Potential Anti-Alzheimer's Disease Agents.

Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease

Newly synthesized Bis-Hydrazono[1,3,4] thiadiazoles as Anti-Alzheimer's Agents: Greener past and In-Vitro acetylcholinesterase inhibition assay investigations

Design, synthesis and evaluation of imidazo[1,2-a]pyrazin-8(7H)-one derivatives as acetylcholinesterase inhibitors and antioxidants

Design, Synthesis and Evaluation of 8‐(Piperazin‐1‐yl) Imidazo[1,2‐a]Pyrazine Derivatives as Acetylcholinesterase Inhibitors and Antioxidants